| Abstrakt: |
Purpose : The aim of this study was to analyse the impact of adjuvant trastuzumab on fatigue, emotional status, and quality of personal and work life of patients treated for localised breast cancer. Methods: In a prospective setting, we recruited age-matched localised breast cancer patients, treated by adjuvant chemotherapy with (group 1) or without IV trastuzumab (group 2), between September 2011 and May 2014. Patients completed questionnaires on quality of life (FACT-G, FACT-B), fatigue (FACIT-F, ICQ), anxiety-depression (HADS), and work life (dedicated self-questionnaire) at inclusion then at 3, 6, 9, and 15 months. Results: We included 35 patients in each group. No significant difference was found between the two groups concerning return to work, fatigue, and quality of life scores at each phase of the study. In total, 39 patients (72.2%) reported having returned to work at T15, with no significant difference between the two groups (p = 0.53). Significantly higher scores for’helplessness’ outcomes were observed in group 1, 9, and 15 months (6.138 and 5.731; p = 0.047 and 0.048, respectively). Patients in group 1 reported higher score of anxiety-depression than group 2 at 3 months (p = 0.027) then no significant difference was observed at the other times of the study. Conclusion: Trastuzumab does not appear to affect fatigue and return to work in patients with localised breast cancer. The emotional well-being could be affected in patients treated by trastuzumab, with a more pronounced ‘helplessness’ feeling which could be more related to the additional follow-up imposed by the prescription of trastuzumab.Highlights: One year of trastuzumab treatment is recommended for patients with localised breast cancer presenting with overexpression of HER2. The own impact of trastuzumab treatment on the physical, emotional, social, and professional well-being of patients has not already been described. In our study, trastuzumab treatment does not appear to affect fatigue and return to work in patients with localised breast cancer. The emotional well-being could be affected in patients treated by trastuzumab, with a more pronounced ‘helplessness’ feeling. Our results suggest that observed differences seem to be more related to the additional follow-up imposed by the prescription of trastuzumab. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink